Data on the role of tau, spastin, and the long chain polyglutamylation enzyme in Alzheimer’s disease and hereditary spastic paraplegia, along with therapeutic options were summarized previously in a comprehensive review paper (Zempel and Mandelkow 2015). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.